Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers

Human Pathology

Volumn 41, Issue 11, 2010, Pages 1577-1585

  Marx, Andreas H ^a   Burandt, Eike C ^a   Choschzick, Matthias ^a   Simon, Ronald ^a   Yekebas, Emre ^a   Kaifi, Jussuf T ^a   Mirlacher, Martina ^a   Atanackovic, Djordje ^a   Bokemeyer, Carsten ^a   Fiedler, Walter ^a   Terracciano, Luigi ^b   Sauter, Guido ^a   Izbicki, Jakob R ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Colorectal cancer; FISH; HER 2; Immunohistochemistry; TMA; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; UNCLASSIFIED DRUG; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR LOCALIZATION; ADENOCARCINOMA; COLORECTAL TUMOR; ENZYME IMMUNOASSAY; EPIDEMIOLOGY; GENETICS; GERMANY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROTO ONCOGENE; SECONDARY; SURVIVAL RATE; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DNA, NEOPLASM; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; GERMANY; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; RECEPTOR, ERBB-2; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; KAPLAN-MEIER ESTIMATE;

EID: 77957953603     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2010.02.018     Document Type: Article

References (40)

1. Akiyama T., Sudo C., Ogawara H., Toyoshima K., and Yamamoto T. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity Science 232 1986 1644 1646 (Pubitemid 16095607)
2. Coussens L., Yang-Feng T.L., and Liao Y.C. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene Science 230 1985 1132 1139
3. Goldenberg M.M. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer Clin Ther 21 1999 309 318
4. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., and McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 1987 177 182
5. Press M.F., Bernstein L., and Thomas P.A. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas J Clin Oncol 15 1997 2894 2904
6. Slamon D.J., Godolphin W., and Jones L.A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 1989 707 712
7. Slamon D.J., Leyland-Jones B., and Shak S. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792
8. Marx A.H., Tharun L., and Muth J. HER-2 amplification is highly homogenous in gastric cancer Hum Pathol 40 2009 769 777
9. Cappuzzo F., Varella-Garcia M., and Shigematsu H. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients J Clin Oncol 23 2005 5007 5018
10. Tapia C., Glatz K., and Novotny H. Close association between HER-2 amplification and overexpression in human tumors of non-breast origin Mod Pathol 20 2007 192 198
11. Reichelt U., Duesedau P., and Tsourlakis M. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus Mod Pathol 20 2007 120 129
12. Safran H., DiPetrillo T., and Nadeem A. Trastuzumab, paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: a phase I study Cancer Invest 22 2004 670 677
13. Ramanathan R.K., Hwang J.J., and Zamboni W.C. Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial Cancer Invest 22 2004 858 865
14. Kim S.Y., Kim H.P., and Kim Y.J. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin Int J Oncol 32 2008 89 95
15. Mihaljevic A., Buchler P., and Harder J. A prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancer BMC Surg 9 2009 1
16. Van Cutsem E., Kang Y., and Chung H. Efficacy results from the ToGA trial: aphase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC) J Clin Oncol 27 2009 18s
17. Park D.I., Kang M.S., and Oh S.J. HER-2/neu overexpression is an independent prognostic factor in colorectal cancer Int J Colorectal Dis 22 2007 491 497
18. Kavanagh D.O., Chambers G., and O'Grady L. Is overexpression of HER-2 a predictor of prognosis in colorectal cancer? BMC Cancer 9 2009 1
19. Ooi A., Takehana T., and Li X. Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study Mod Pathol 17 2004 895 904
20. Ismail H.M., El-Baradie M., Moneer M., Khorshid O., and Touny A. Clinico-pathological and prognostic significance of p53, Bcl-2 and Her-2/neu protein markers in colorectal cancer using tissue microarray J Egypt Natl Canc Inst 19 2007 3 14
21. Al-Kuraya K., Novotny H., and Bavi P. HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer J Clin Pathol 60 2007 768 772
22. Nathanson D.R., Culliford A.T.t., and Shia J. HER 2/neu expression and gene amplification in colon cancer Int J Cancer 105 2003 796 802
23. Simon R., Nocito A., and Hubscher T. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer J Natl Cancer Inst 93 2001 1141 1146
24. Sauter G., Moch H., and Moore D. Heterogeneity of erbB-2 gene amplification in bladder cancer Cancer Res 53 1993 2199 2203
25. Lugli A., Zlobec I., and Baker K. Prognostic significance of mucins in colorectal cancer with different DNA mismatch-repair status J Clin Pathol 60 2007 534 539
26. Simon R., Mirlacher M., and Sauter G. Tissue microarrays Methods Mol Med 114 2005 257 268
27. Bubendorf L., Kononen J., and Koivisto P. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays Cancer Res 59 1999 803 806
28. Schraml P., Kononen J., and Bubendorf L. Tissue microarrays for gene amplification surveys in many different tumor types Clin Cancer Res 5 1999 1966 1975
29. Hofmann M., Stoss O., and Shi D. Assessment of a HER2 scoring system for gastric cancer: results from a validation study Histopathology 52 2008 797 805
30. Schuell B., Gruenberger T., Scheithauer W., Zielinski C., and Wrba F. HER 2/neu protein expression in colorectal cancer BMC Cancer 6 2006 123
31. Kountourakis P., Pavlakis K., and Psyrri A. Clinicopathologic significance of EGFR and Her-2/neu in colorectal adenocarcinomas Cancer J 12 2006 229 236
32. Kapitanovic S., Radosevic S., and Kapitanovic M. The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer Gastroenterology 112 1997 1103 1113
33. Tavangar S.M., Shariftabrizi A., and Soroush A.R. Her-2/neu over-expression correlates with more advanced disease in Iranian colorectal cancer patients Med Sci Monit 11 2005 CR123 CR126
34. Pavlakis K., Kountourakis P., and Stathopoulos E. Her-2 protein expression, cellular localization, and gene amplification in colorectal carcinoma Appl Immunohistochem Mol Morphol 15 2007 441 445
35. Antonacopoulou A.G., Tsamandas A.C., and Petsas T. EGFR, HER-2 and COX-2 levels in colorectal cancer Histopathology 53 2008 698 706
36. Arnould L., Arveux P., and Couturier J. Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification Clin Cancer Res 13 2007 6404 6409
37. Gullo G., Bettio D., Torri V., Masci G., Salvini P., and Santoro A. Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer Invest New Drugs 27 2009 179 183
38. Sauter G., Lee J., Bartlett J.M., Slamon D.J., and Press M.F. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations J Clin Oncol 27 2009 1323 1333
39. Dawood S., Gonzalez-Angulo A.M., and Peintinger F. Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience Cancer 110 2007 1195 1200
40. Adamo V., Franchina T., and Adamo B. Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study) Ann Oncol 18 Suppl 6 2007 vi11 vi15